所有图片(1)

文件

C2210000

顺氯氨铂

Name: 顺氯氨铂
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

顺铂, 顺-二氯二氨基铂(II), 顺式-二胺二氯铂, 顺氯氨铂

登录查看公司和协议定价

所有图片(1)

About This Item

线性分子式:

Pt(NH₃)₂Cl₂

CAS号:

15663-27-1

分子量:

300.05

EC 号:

239-733-8

MDL编号:

MFCD00011623

UNSPSC代码:

41116107

PubChem化学物质编号:

329774978

NACRES:

NA.24

等级

pharmaceutical primary standard

API类

cisplatin

制造商/商品名称

EDQM

mp

270 °C (lit.)

应用

pharmaceutical (small molecule)

格式

neat

SMILES字符串

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

InChI key

LXZZYRPGZAFOLE-UHFFFAOYSA-L

正在寻找类似产品? 访问产品对比指南

一般描述

本品按现行药典规定交付。所有为支持本产品而提供的信息，包括 SDS 和任何产品信息小册子，均由药典颁发机构制定和发布。

如需进一步的信息和支持，请访问现行药典网站。

应用

本欧洲药典参考标准仅用于欧洲药典中明确规定的用途。不保证适用于任何其他用途，用户请自行负责。本标准品不适用于人类或动物使用。
根据欧洲药典，用于配制下列给定溶液：

鉴定参考溶液，根据各论 0559，采用红外吸收光谱法和薄层色谱法检测相关物质，使用采用液相色谱法（通则 2.2.29）检测顺铂
参考溶液 (b)，根据各论 1081，使用液相色谱法（通则 2.2.29）检测异麦芽酮糖醇中的相关物质

生化/生理作用

强效的铂基抗肿瘤剂。与 DNA 二核苷酸 d(pGpG) 形成细胞毒性加合物，诱导链内交联。

包装

本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。

其他说明

相应销售限制条件可能适用。

警示用语：

Danger

危险声明

H300,H315,H317,H319,H334,H335,H350

预防措施声明

P202 - P261 - P280 - P301 + P310 - P302 + P352 - P305 + P351 + P338

危险分类

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

靶器官

Respiratory system

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Cisplatin

European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare

European pharmacopoeia, 2231-2232 (2009)

Carboplatin

European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare

European pharmacopoeia, 6104-6105 (2022)

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Yi-Long Wu et al.

The Lancet. Oncology, 14(8), 777-786 (2013-06-21)

The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients with advanced non-small-cell lung cancer. We undertook FASTACT-2, a phase 3 study in a similar patient population.

High tumor interstitial fluid pressure identifies cervical cancer patients with improved survival from radiotherapy plus cisplatin versus radiotherapy alone.

Michael F Milosevic et al.

International journal of cancer, 135(7), 1692-1699 (2013-08-02)

Radiotherapy (RT) with concurrent cisplatin (CRT) is standard treatment for locally advanced cervical cancer. However, not all patients benefit from the addition of cisplatin to RT alone. This study explored the value of pretreatment tumor interstitial fluid pressure (IFP) and

Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.

Vicente Fresquet et al.

Blood, 123(26), 4111-4119 (2014-05-03)

Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on its high affinity for BCL2, we studied potential mechanisms conferring

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件